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Abstract
Background: Alternative splicing and polyadenylation are important mechanisms for creating the
proteomic diversity necessary for the nervous system to fulfill its specialized functions. The
contribution of alternative splicing to proteomic diversity in the nervous system has been well
documented, whereas the role of alternative polyadenylation in this process is less well
understood. Since the CstF-64 polyadenylation protein is known to be an important regulator of
tissue-specific polyadenylation, we examined its expression in brain and other organs.
Results: We discovered several closely related splice variants of CstF-64 – collectively called
βCstF-64 – that could potentially contribute to proteomic diversity in the nervous system. The
βCstF-64 splice variants are found predominantly in the brains of several vertebrate species
including mice and humans. The major βCstF-64 variant mRNA is generated by inclusion of two
alternate exons (that we call exons 8.1 and 8.2) found between exons 8 and 9 of the CstF-64 gene,
and contains an additional 147 nucleotides, encoding 49 additional amino acids. Some variants of
βCstF-64 contain only the first alternate exon (exon 8.1) while other variants contain both
alternate exons (8.1 and 8.2). In mice, the predominant form of βCstF-64 also contains a deletion
of 78 nucleotides from exon 9, although that variant is not seen in any other species examined,
including rats. Immunoblot and 2D-PAGE analyses of mouse nuclear extracts indicate that a protein
corresponding to βCstF-64 is expressed in brain at approximately equal levels to CstF-64. Since
βCstF-64 splice variant family members were found in the brains of all vertebrate species examined
(including turtles and fish), this suggests that βCstF-64 has an evolutionarily conserved function in
these animals. βCstF-64 was present in both pre- and post-natal mice and in different regions of
the nervous system, suggesting an important role for βCstF-64 in neural gene expression
throughout development. Finally, experiments in representative cell lines suggest that βCstF-64 is
expressed in neurons but not glia.
Conclusion: This is the first report of a family of splice variants encoding a key polyadenylation
protein that is expressed in a nervous system-specific manner. We propose that βCstF-64
contributes to proteomic diversity by regulating alternative polyadenylation of neural mRNAs.
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Background
Alternative mRNA processing is the mechanism by which
multiple forms of mRNAs are generated from a common
pre-mRNA via differential ligation of exons (alternative
splicing, [1]), or differential 3' end site choice (alternative
polyadenylation, [2]). Alternative mRNA processing con-
tributes to proteomic diversity by generating protein iso-
forms that have different biochemical and structural
properties [3,4]. Both of these processes are regulated in a
tissue-specific manner, with the highest incidence occur-
ring in the nervous system [5-7]. Not surprisingly, the
processes of splicing and polyadenylation are coupled,
leading to a high degree of interaction between the two
processing machineries [8,9]. However, there have been
only a few reports of alternative processing of mRNAs
encoding critical proteins of the polyadenylation machin-
ery: alternative splicing of poly(A) polymerase (PAP, [10])
and alternative splicing and polyadenylation of the 77
kDa subunit of the cleavage stimulation factor (CstF-77)
in Drosophila [11] and mammals [12] have been
reported. Alternatively spliced forms of these and other
polyadenylation proteins could contribute to expansion
of the proteome by promoting tissue-specific polyade-
nylation.
Like splicing, polyadenylation is an essential step in gene
expression. The process of 3' end formation promotes
transcription termination, mRNA export from the nucleus
to the cytosol, mRNA stability, and translation initiation
[13,14]. In addition to having a constitutive role in gene
expression, polyadenylation also contributes to the gener-
ation of mRNA isoforms in a tissue-specific manner, par-
ticularly in the nervous system. For example, the mRNAs
encoding β-adducin [15], huntingtin [16], amyloid pre-
cursor protein [17], ferritin heavy chain [18,19], gluta-
mate transporter EAAT2 [20], voltage-gated potassium
channel [21], 68-kDa neurofilament [22], and many
other proteins [23-28] have alternative polyadenylation
signals that lead to production of nervous system-specific
transcripts. Nervous system-specific coupling of alterna-
tive splicing and polyadenylation of mRNAs encoding cal-
citonin/calcitonin gene-related peptide [29], neural cell
adhesion molecule [30], and vesl-1/homer1 [31] proteins
lead to generation of tissue-specific protein isoforms from
a common pre-mRNA. It has been speculated that use of
alternative polyadenylation signals in these mRNAs may
be due to expression of nervous system-specific polyade-
nylation factors [32], although none have been reported.
CstF-64 is a key subunit of the polyadenylation complex
that is known to function in regulation of polyadenyla-
tion [33,34]. Important domains of CstF-64 include an
RNA-binding domain [35-38], CstF-77 interaction
domain [39], proline/glycine-rich domain [36], MEARA
repeat domain [40], and a conserved C-terminal domain
[41]. Furthermore, a paralogous form of CstF-64, τCstF-
64, was previously discovered in mouse male germ cells
[42] and was found to be essential for normal sperma-
togenesis [43].
In this paper, we report the discovery of a family of alter-
natively spliced forms of the CstF-64 mRNA that are
expressed in the nervous system of all vertebrate animals
we have examined. These splice variants, which we collec-
tively call βCstF-64, are due to inclusion of one or two
alternate exons between constitutive exons 8 and 9. In
mice, these alternate exons join to an alternative 3' splice
site within exon 9. Mice express another minor splice var-
iant, αCstF-64, which is formed by joining of exon 8 to
the alternative 3' splice site in exon 9. However, the αCstF-
64 splice variant was not observed in any other species
including rats or humans. All the βCstF-64 splice variants
are in-frame with the CstF-64 coding region and encode
up to 49 additional amino acids in the proline/glycine-
rich domain. The βCstF-64 splice variants are expressed in
brains of many vertebrate species, including human and
turtle, and the genome of simple vertebrates such as puff-
erfish and zebrafish contain homologous sequences. This
leads us to hypothesize that the βCstF-64 variants have an
important evolutionarily conserved role in brain func-
tion. Other experiments suggest that βCstF-64 is expressed
predominantly in neurons, suggesting that it plays a role
in expression of alternatively polyadenylated mRNAs
important for neuronal function, thus contributing to
proteomic diversity in the nervous system.
Results
Alternatively spliced CstF-64 mRNAs are present in mouse 
brain
Previous results from our laboratory indicated that CstF-
64 mRNA could be subject to alternative splicing (B. Dass
and A. M. Wallace, unpublished). In order to investigate
this possibility, we conducted an RT-PCR survey of CstF-
64 mRNA in mouse tissues using primers that together
span the entire CstF-64 coding region (Figure 1). RNA was
isolated from various mouse tissues as indicated and sub-
jected to RT-PCR using primer pairs A, B, C and D that
span exons 1–5, 5–8, 7–11 and 9–14 respectively (Figure
1A). RT-PCR with primer pairs A, B, and D yielded a single
PCR product in all tissues that corresponded to the
reported form of CstF-64 (Figure 1B, panels a, b, d, lanes
1–8). This suggests little or no alternative splicing
between exons 1–8 and 9–14. However, RT-PCR using
primer pair C (which spans exons 7–11) resulted in mul-
tiple PCR products (Figure 1B, panel c). Every mouse tis-
sue examined showed the presence of the reported form
of CstF-64 (595 bp) and a shorter splice variant that we
named  αCstF-64 (panel c, lanes 1–8). Cloning and
sequencing of the αCstF-64 PCR product indicated that
the shorter splice variant of CstF-64 was generated by join-
ing of exon 8 to an alternative 3' splice site in exon 9BMC Molecular Biology 2009, 10:22 http://www.biomedcentral.com/1471-2199/10/22
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resulting in an mRNA molecule shorter by 78 nucleotides
(Figure 1C). We reported this alternatively spliced form to
GenBank as αCstF-64, variant 4 (GenBank: EU616681).
The αCstF-64 splice variant is in frame with exon 9, and
should result in a protein isoform that is shorter by 26
amino acids (not tested, but see Figure 2C). Since the
αCstF-64 splice variant was not expressed in any other
species we examined (see below), we chose not to charac-
terize it further.
Surprisingly, using primer pair C, we found that brain had
a larger PCR product (664 bp) that was absent from all the
other tissues (Figure 1B, panel c, compare lane 1 to lane
2–8). Cloning and sequencing of the larger PCR product
revealed that it contained an additional 147 nucleotides
between exon 8 and the αCstF-64 splice site within exon
9 (see Additional File 1 for nucleotide sequence). We
named the alternate exons 8.1 and 8.2, and the longer
brain-expressed variant CstF-64, βCstF-64. The above
form of mouse βCstF-64 containing exons 8.1, 8.2 and use
of alternative 3' splice site was given the GenBank nomen-
clature βCstF-64, variant 1 (GenBank: EU616682.1). We
compared the sequence of the βCstF-64 variant region to
the mouse genome and determined that βCstF-64 was
generated by splicing of two alternate exons (8.1 and 8.2,
Figure 1C) from the intronic region between exons 8 and
9 and selection of an alternative 3' splice site in exon 9.
Exons 8.1 and 8.2 contained 60 and 87 nucleotides
respectively. The alternative splicing patterns suggests that
βCstF-64 remains in-frame with the CstF-64 coding
region, and that it encodes an expressed protein isoform
of CstF-64. The predicted domain structure of the protein
isoform encoded by βCstF-64 mRNA is illustrated in Fig-
ure 1D; this predicted protein isoform would lack 26
amino acids in the proline/glycine-rich domain of CstF-
64 encoded by exon 9 and contain an additional 49
amino acids encoded by exons 8.1 and 8.2 (Figure 1D).
BLAST comparison of the brain-expressed βCstF-64
domain to all sequences in GenBank revealed no other
described proteins with similar features (not shown).
Thus, these data suggest that mouse βCstF-64 mRNA
encodes a protein in brain that is 23 amino acids longer
than CstF-64, containing a unique 49 amino acid brain-
specific domain.
The βCstF-64 protein isoform is expressed in mouse brain
In order to investigate whether the βCstF-64 protein was
expressed in mouse brain, antibodies were raised against
16 amino acids of the unique 49 amino acid domain of
the protein (Materials and Methods). The specificity of the
anti-βCstF-64 antibody was tested using recombinant
βCstF-64 and CstF-64 proteins expressed in HeLa cells
(Figure 2A). Plasmids encoding epitope-tagged
(3XFLAG)-βCstF-64 and CstF-64 proteins were transfected
into HeLa cells as described in "Materials and Methods".
An alternatively spliced mRNA of CstF-64 is present in  mouse brain Figure 1
An alternatively spliced mRNA of CstF-64 is present 
in mouse brain. A) Gene structure of CstF-64 and location 
of primer pairs. Boxes indicate exons; black line indicates 
introns; exons 8 and 9 are in red while all the other exons 
are black; the 3' UTR is blue. B) RT-PCR analysis of alterna-
tively spliced mRNAs of CstF-64. RNA from indicated mouse 
tissues was subjected to RT-PCR using primer pairs A, B, C, 
and D (panels a, b, c, and d respectively). Sizes of amplified 
products are indicated at the right. Panel e (-RT) denotes 
RT-PCR using primer pair C with no reverse transcriptase 
added. C) Splicing patterns in CstF-64 mRNA. a) CstF-64 
genomic structure showing exon 8, 9 and the intervening 
intron. Boxes indicate exons and horizontal lines indicate 
introns; vertical lines indicate splicing patterns. The thin 
white line in exon 9 denotes the alternative 3' splice site. b) 
Splicing pattern of the regular form of CstF-64 mRNA. c) 
Splicing pattern of the shorter CstF-64 mRNA (αCstF-64). 
d) Splicing pattern of βCstF-64 mRNA. The sizes of the 
βCstF-64-specific exons (8.1 and 8.2) are indicated. D) Pre-
dicted domain structures of mouse CstF-64 and βCstF-64. 
Shown are the RNA-binding domains (RBD, dark gray), the 
region of interaction with CstF-77 (77-BD, light gray), the 
proline/glycine domain (Pro/Gly, white box), MEARA repeat 
domain (12× MEARA, dark gray) and the conserved C-termi-
nal domain (CTD, light gray). The region within the Pro/Gly 
domain that contains a deletion of 26 amino acids is indicated 
by vertical lines, and the 49 amino acid βCstF-64-specific 
domain is indicated by the black box.BMC Molecular Biology 2009, 10:22 http://www.biomedcentral.com/1471-2199/10/22
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Whole cell lysates were prepared and subjected to SDS-
PAGE and immunoblot analysis using anti-βCstF-64 (Fig-
ure 2A, top panel), anti-FLAG (Figure 2A, middle panel),
and anti-tubulin antibodies (Figure 2A, bottom panel).
This experiment demonstrated that the βCstF-64 epitope
was not detected in HeLa cells (lane 1) or in HeLa cells
transfected with FLAG-CstF-64 (lane 2) but was expressed
at the predicted size in HeLa cells transfected with FLAG-
βCstF-64 (lane 3) suggesting that the anti-βCstF-64 anti-
body could uniquely distinguish CstF-64 and βCstF-64 in
mammalian cells.
Next, expression of βCstF-64 protein in various mouse tis-
sues was investigated using the anti-βCstF-64 antibody.
Nuclear extracts from the indicated mouse tissues were
subjected to immunoblot analysis using the anti-βCstF-64
and anti-CstF-64 antibodies (Figure 2B). Using the anti-
CstF-64 antibody, CstF-64 was detected in all tissues (Fig-
ure 2B, lower panel). In contrast, using the anti-βCstF-64
antibody, a protein of approximately 68 kDa was detected
in brain but not in other tissues examined (Figure 2B,
upper panel, compare lanes 1 and 2–7). Detection of this
protein was blocked by preincubation of the antibody
with the 16 amino acid peptide that was used as an immu-
nogen (lane 9). These results suggest that while the CstF-
64 protein is expressed in most or all tissues [44], the
βCstF-64 isoform is restricted to brain and probably other
neural tissues.
βCstF-64 and CstF-64 protein levels are similar in mouse 
brain
We wanted to investigate the relative levels of the CstF-64
and βCstF-64 proteins in mouse brain. Since we could not
resolve βCstF-64 from CstF-64 proteins in a single dimen-
sion (Figure 2B and data not shown), 2D-PAGE analysis
was employed to investigate this. Nuclear extracts from
mouse brain and liver were resolved in the first dimension
by isoelectric focusing and in the second dimension by
SDS-PAGE [45]. Using the anti-CstF-64 antibody, at least
two closely opposed patterns of spots were detected in
brain (Figure 2C, panel a) while a single pattern of spots
was detected in liver (Figure 2C, panel c). The basic to
acidic range of spots most likely reflects differential phos-
pohorylation of CstF-64 [36,46]. Identical blots were
probed with the anti-βCstF-64 antibody, and only a single
pattern of spots was detected in brain (Figure 2C, panel
b), while no signal was detected in liver (panel d). Align-
ment of the anti-CstF-64 blot (panel a) with the anti-
βCstF-64 blot (panel b) confirmed that the anti-βCstF-64
pattern overlapped with the upper pattern in the anti-
CstF-64 blot. This suggested that only the upper pattern
detected in brain by the anti-CstF-64 antibody contained
the βCstF-64 epitope. Judging by the relative intensities of
the two patterns of spots in brain (panel a), we estimate
that the protein levels of CstF-64 and βCstF-64 are approx-
The βCstF-64 protein is expressed predominantly in mouse  brain Figure 2
The βCstF-64 protein is expressed predominantly in 
mouse brain. A) Whole cell extracts from HeLa cells 
transfected with 800 ng of either 3XFLAG (lane 1), 3XFLAG-
CstF-64 (lane 2) or 3XFLAG-βCstF-64 (lane 3) were sub-
jected to immunoblot analysis using anti-βCstF-64 (upper 
panel), anti-FLAG (middle panel), or anti-α-Tubulin (lower 
panel) antibodies. The apparent molecular weights of 
3XFLAG-CstF-64, 3XFLAG-βCstF-64, and tubulin are indi-
cated at left. B) Protein immunoblot detection of βCstF-64 
in various mouse tissues. Nuclear extracts from indicated 
mouse tissues were subjected to immunoblot analysis using 
pre-immune serum (lane 8), peptide-blocked anti-βCstF-64 
antibody (lane 9), anti-βCstF-64 antibody (upper panel, lanes 
1–7), or anti-CstF-64 antibody (lower panel, lanes 1–7). The 
apparent molecular weights of CstF-64 and βCstF-64 are 
indicated at left. C) 2D-PAGE analysis of mouse brain and 
liver nuclear extracts. Nuclear extracts were resolved in the 
first dimension by isoelectric focusing on a pH 3–10 immo-
biline strip as indicated. The proteins were then resolved in 
the second dimension by denaturing PAGE, transferred to 
nitrocellulose membrane and probed with the anti-CstF-64 
antibody (panels a and c) or anti-βCstF-64 antibody (panels 
b and d). The arrows denote CstF-64 and βCstF-64. The 
asterisk in panels a and c indicates a pattern that may be 
αCstF-64.BMC Molecular Biology 2009, 10:22 http://www.biomedcentral.com/1471-2199/10/22
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imately the same in mouse brain. Interestingly, a faint pat-
tern of spots is seen in both brain and liver using the anti-
CstF-64 antibody (panels a and c, asterisks). We speculate
that this might represent the mouse-specific αCstF-64 pro-
tein isoform.
The βCstF-64 family of splice variants is evolutionarily 
conserved
In order to determine whether βCstF-64 was also
expressed in brains of other mammalian species, RT-PCR
analysis was conducted using human RNA samples (Fig-
ure 3A). RT-PCR analysis using human-specific primers
flanking exons 8 and 9 (Table 1) indicated that CstF-64
mRNA was present in brain, liver and testis (Figure 3A,
lanes 1–3). A larger PCR product was detected in human
brain RNA (Figure 3A, lane 1). Smaller amounts of this
product were also detected in human testis (lane 3). Clon-
ing and sequencing of the larger PCR product from
human brain revealed a product that contained only exon
8.1 and lacked exon 8.2 and use of the alternative 3' splice
site. This demonstrated that the alternatively spliced
βCstF-64 isoform in human brain differed from that in
mice. We named this isoform, βCstF-64 variant 2 (Gen-
Bank: EU616679.1). However, EST database searches
(NCBI) showed that mRNAs containing exon 8.1 joined
to exon 8.2 were found in humans (Accession numbers:
AK095684.1, DA513594.1 and wild boar (Accession
number: AJ959057.1). Therefore, using primers specific to
the predicted exon 8.2, we detected mRNAs containing
this exon in humans (data not shown). We have never
observed a βCstF-64 variant mRNA (either by database
searches or by cloning) containing exon 8 joined to exon
8.2 in either humans, mice or any other mammals. The
βCstF-64 mRNA that contained both exons 8.1 and 8.2
but lacked use of the alternative 3' splice site in exon 9 was
given the GenBank nomenclature, βCstF-64 variant 3
(GenBank: EU616680.1). These data suggested that both
βCstF-64 variant 2 (exon 8.1 only) and βCstF-64 variant 3
(exon 8.1 and 8.2) are expressed in human brain. The
βCstF-64 variant 3 mRNA was also detected in the brains
of the mouse species Mus spretus and in rats (data not
shown). No product corresponding to αCstF-64 was seen
in any of the human samples (lanes 1–3).
We wanted to determine whether the βCstF-64 variant
family was restricted to mammals, or could be detected in
other vertebrate species. Therefore, RT-PCR analysis was
conducted using RNA from brain and liver of turtle (Tra-
chemys scripta elegans). RT-PCR products corresponding to
βCstF-64 mRNA were detected in turtle brain (Figure 3,
lane 7) but not liver (Figure 3, lane 8). Cloning and
sequencing of the band revealed that its splicing pattern
Table 1: Primers used in detection and analysis of CstF-64 splice variants
Species Primer Name Primer Sequence
Mouse Pair A 5' GGGTGAGCCATGGCGGGTT 3'
5' CTGTTCTGGTGGAAGACTGGCAA 3'
Mouse Pair B 5' CCCCAGGAAGCACGAAACA 3'
5' CCTCGTTCCATGGGCACTG 3'
Mouse, Rat Pair C 5' CAATGGCGCACCTCCTATGATG 3'
5' GGCACGGGCTTCCAGTCCT 3'
Mouse Pair D 5' GATTAGATGCACGGGGGATGGA 3'
5' TGGAGCAATGGCGATGTAAGACC 3'
Human Pair C 5' CCCCTCAGGCCCAGTCTTTG 3'
5' TGGCCCTCCCCTCAGTTCAT 3'
Turtle Pair C 5' GACAGATGCCAGCCTCCGTAGC 3'
5' CCATTGGTCCTCCCCTCATTTCAT 3'
Mouse X 5' CAATGGCGCACCTCCTATGATG 3'
Mouse Y 5' TTCCACCTTGCATGCTTGCTC 3
Mouse E 5 ' GATCTATGGCGGGTTTGCCAGTGAG 3'
Mouse F 5 ' TCTAGATCAAGGTGCCCCAGTGGATTTC 3
Nucleotide sequences of the various primer pairs used in this study are indicated at right. The names of primer pairs along with their corresponding 
species are indicated at left in the table.BMC Molecular Biology 2009, 10:22 http://www.biomedcentral.com/1471-2199/10/22
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was similar to βCstF-64 variant 2 mRNA observed in
human (Figure 3B). RT-PCR analysis suggested that βCstF-
64 mRNA with a splicing pattern similar to that observed
in turtle was also present in ground squirrel, alligator, and
Monodelphis (not shown, summarized in Figure 3B).
Database searches using exons 8.1 and 8.2 as query were
conducted to determine the distribution of βCstF-64 in
various animal species (Figure 3B and Additional File 2).
Comparison of mouse βCstF-64 nucleotide sequence to
the human genome showed that exon 8.1 was 98% iden-
tical whereas exon 8.2 was 96% identical. The nucleotide
sequence of exons 8.1 and 8.2 were 96% identical when
compared to that of rhesus monkey (Macaca mulatta).
Additionally, survey of the whole-genome-shotgun
sequence database at NCBI showed a high degree of con-
servation of exons 8.1 and 8.2 in the genomes of other
mammalian species such as guinea pig, horse, cat, and
others. Finally, using BLASTX and BLASTP searches at the
NCBI database, amino acids encoded by exon 8.1 were
predicted to be present in proteins from chimpanzee, cow,
dog (eutherian mammals), platypus (monotreme), Xeno-
pus (amphibian), pufferfish, and zebrafish (fish). We
note that exon 8.2 was not explicitly observed in these
species, but the incomplete nature of some of these
genome data sets does not allow us to rule out its pres-
ence. The high degree of conservation in vertebrate animal
species suggests an essential function for the βCstF-64
family of splice variants in neural mRNA polyadenylation.
βCstF-64 mRNA is present throughout the mouse nervous 
system
An RT-PCR approach was used to investigate the expres-
sion of βCstF-64 mRNA in mouse nervous system. RNA
was isolated from mouse spinal cord and five different
regions of the brain (cerebrum, cerebellum, brain stem,
diencephalon and olfactory bulb). βCstF-64 mRNA was
detected in all five brain regions (Figure 4, lanes 3–7) and
in spinal cord, but not in adrenal gland (Figure 4, lane 8),
consistent with nervous system-predominant expression
of βCstF-64. RT-PCR of ribosomal S16 mRNA was used to
assess RNA loading (Figure 4, lower panel).
βCstF-64 mRNA is not present in glial cell lines examined
We wanted to determine in which neural cell types (neu-
rons or glia) βCstF-64 was expressed. For this, RNAs from
various rodent and human neuronal and glial cell lines
were subjected to RT-PCR using species-specific primers
flanking exons 8 and 9 of the CstF-64 gene (Figure 5). The
rat and human thyroid carcinoma cell lines (CA77, Figure
5A, lane 5 and TT, Figure 5B, lane 2) used in this study
have a neuronal phenotype and are neuroendocrine in
nature [47,48]. The PC-12 cell line (Figure 5A, lane 6)
derived from rat adrenal chromaffin cells, is neuroendo-
crine in nature, and, when treated with nerve growth fac-
tor (NGF, lane 7), differentiates into a cell that resembles
the sympathetic neurons in the peripheral nervous system
[49]. βCstF-64 mRNA was detected in CA77 (Figure 5A,
lane 5), undifferentiated and NGF-differentiated PC-12
cell lines (Figure 5, lanes 6 and 7), TT (Figure 5B, lane 2),
and SK neuroblastoma cell lines (Figure 5B, lane 3). Inter-
estingly, the expression of βCstF-64 mRNA appeared to
The βCstF-64 family of splice variants is evolutionarily con- served in vertebrates Figure 3
The βCstF-64 family of splice variants is evolutionar-
ily conserved in vertebrates. A) RT-PCR analysis of 
human and turtle CstF-64 mRNAs. Human brain, liver, and 
testis RNAs were subjected to RT-PCR using primers flank-
ing exons 8 and 9 of the human CstF-64 gene (lanes 1–6). 
RNA isolated from brain and liver of adult turtle was sub-
jected to RT-PCR analysis using primers flanking exons 8 and 
9 of the turtle CstF-64 gene (lanes 7–10). RT-PCR with no 
reverse transcriptase (-RT) is shown in lanes 4–6 (left panel) 
and lanes 9, 10 (right panel). B) Alternative splicing patterns 
of CstF-64 in various animal species. The splicing pattern of 
CstF-64 is shown on top. The distributions of the βCstF-64 
variant mRNAs in different animal species is as follows: 
βCstF-64, variant 1: Mus musculus; βCstF-64, variant 2: chim-
panzee (Pan troglodytes), bovine (Bos taurus), dog (Canis famil-
iaris), thirteen-lined ground squirrel (Spermophilus 
tridecemlineatus), gray short-tailed opossum (Monodelphis 
domestica), African clawed toad (Xenopus laevis), duck-billed 
platypus (Ornithorhynchus anatinus), zebrafish (Danio rerio), 
and pufferfish (Tetraodon nigroviridis); βCstF-64, variant 3: 
Algerian mouse (Mus spretus), rat (Rattus norvegicus), human 
(Homo sapiens), pig (Sus scrofa domestica); βCstF-64, variant 4: 
mouse (Mus musculus). The splicing patterns of βCstF-64 
mRNA in mice (Mus musculus and Mus spretus), rat, human, 
ground squirrel, short-tailed opossum, alligator, and turtle 
were determined from cloning and sequencing of RT-PCR 
products. The splicing patterns for chimpanzee, bovine, dog, 
toad, platypus, zebrafish, and pufferfish were obtained by 
searches of EST and protein databases utilizing BLASTX and 
BLASTP programs (not shown).BMC Molecular Biology 2009, 10:22 http://www.biomedcentral.com/1471-2199/10/22
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increase in PC-12 cells treated with nerve growth factor
(NGF, lane 7). βCstF-64 mRNA was not detected in mouse
P19 embryonic carcinoma cell line (Figure 5A, lane 3),
and NB41A3 neuroblastoma cell line (Figure 5A, lane 2).
In contrast, βCstF-64 was not detected in any of the
human glial cell lines tested (Figure 5B, lanes 4–7), sug-
gesting that βCstF-64 expression might be restricted to
neurons in the nervous system.
βCstF-64 mRNA is present in mice of all ages
We wanted to investigate the developmental expression of
βCstF-64 in mice (Figure 6). For this experiment, female
mice mated with male mice were examined for the pres-
ence of copulatory plugs. The day copulatory plugs were
found, embryos were designated as day 1 post-coitum (1
dpc). Newborn mice were designated as day 1 postpartum
(1 dpp) and mice at 42 dpp were designated as adult. RNA
from the brains of embryos at 15, 19, 21 dpc, 1 dpp, and
adult male mice was subjected to RT-PCR analysis using
primers flanking exons 8 and 9 of the CstF-64 gene. The
mRNAs corresponding to αCstF-64, CstF-64 and βCstF-64
were detected at 15, 19, and 21 dpc, 1 dpp, and adult mice
(Figure 6, lane 1–5). RT-PCR of ribosomal S16 mRNA was
used to assess RNA loading (Figure 6, lower panel). βCstF-
64 mRNA was also detected in male and female mice of
ages 1 dpp, 5 dpp, 7 dpp, 9 dpp, 13 dpp, 15 and 42 dpp
at approximately equal levels as CstF-64 mRNA (data not
shown).
Discussion and conclusion
While surveying the CstF-64 mRNA for evidence of alter-
native splicing, we made the discovery of a family of alter-
natively spliced forms, collectively called βCstF-64, that
βCstF-64 mRNA is present throughout the mouse nervous  system Figure 4
βCstF-64 mRNA is present throughout the mouse 
nervous system. RT-PCR analysis was performed on RNA 
isolated from the spinal cord, adrenal gland and five regions 
of mouse brain using primer pair C that flanks exons 7–11 of 
the CstF-64 gene. RT-PCR products were resolved by 1% 
agarose gel electrophoresis. RT-PCR of ribosomal S16 
mRNA (lower panel) was used a loading control.
βCstF-64 mRNA expression in neuronal and glial cell lines Figure 5
βCstF-64 mRNA expression in neuronal and glial cell 
lines. RT-PCR analysis of βCstF-64 using exon-specific 
primer pairs (Table S1) from indicated rodent and human 
neuronal and glial cell lines. A) RT-PCR analysis of βCstF-64 
mRNA from mouse brain (lane 1), NB41A3 mouse neurob-
lastoma (lane 2), P19 mouse embryonic carcinoma (lane 3), 
rat brain (lane 4), CA77 rat thyroid carcinoma (lane 5), PC-
12 rat pheochromocytoma (lane 6), or PC-12 rat pheochro-
mocytoma cells treated for 4 days with 50 ng/mL NGF (lane 
7). B) RT-PCR analysis of βCstF-64 mRNA from human 
brain (lane 1), TT thyroid carcinoma (lane 2), SK neuroblast-
oma (lane 3), CHME5 microglia (lane 4), 1321N1 astrocy-
toma (lane 5), A172 astrocytoma (lane 6), or T98G 
glioblastoma cells (lane 7).
βCstF-64 mRNA is present in mice of all ages Figure 6
βCstF-64 mRNA is present in mice of all ages. RT-PCR 
analysis using RNA isolated from brain of day 15 embryo 
(lane 1), day 19 embryo (lane 2), day 21 embryo (lane 3), 
newborn mice (1 dpp, lane 4), and adult male mice (lane 5). 
RT-PCR of ribosomal S16 mRNA (lower panel) was used a 
loading control.BMC Molecular Biology 2009, 10:22 http://www.biomedcentral.com/1471-2199/10/22
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were found exclusively in the brain and spinal cord of
mice and other vertebrate animal species (Figures 1, 3). In
mice, the predominant form of these splice variants
includes two alternate exons (8.1 and 8.2) joined to an
alternative 3' splice site in exon 9, encoding an additional
49 amino acids while deleting 26 amino acids from exon
9. Interestingly, a smaller splice variant, αCstF-64, which
was expressed widely in mice (Figure 1B), was not
observed in non-rodent species, suggesting it arose inde-
pendently of the βCstF-64 variants. We summarized the
nomenclature of these isoforms in Figure 3B. Since our
data demonstrate that the βCstF-64 protein is expressed in
mice (Figure 2), and that the βCstF-64 mRNA family is
present in all vertebrate species examined, we propose
that the βCstF-64 protein variant has an ancient and
essential role in neural function. We hypothesize that
βCstF-64 regulates alternative polyadenylation in these
tissues, leading to greater diversity of neural gene expres-
sion.
A survey of the EST and protein databases (BLASTX and
BLASTP programs) indicated that exon 8.1 was predicted
to be present in mammalian and non-mammalian
genomes. In contrast, a similar analysis showed that exon
8.2 was predicted to be present only in mammalian
genomes. This suggests the possibility that exon 8.2
appeared after the divergence of mammals and other ver-
tebrates, and might serve to supplement the function of
the more ancient exon 8.1. We also found that the
intronic regions between exons 8.1, 8.2 and 9 were highly
conserved between mice and humans (84% identity).
Since the intronic regions and exons 8.1 and 8.2 likely
contain splicing regulatory sequences [50], this supports
the notion that the region between exons 8 and 9 is a "hot
spot" for alternative splicing during evolution. We failed
to detect βCstF-64 exonic sequences in invertebrates such
as Drosophila [51] and the simple chordate Ciona intesti-
nalis [52], leading us to hypothesize that βCstF-64 has a
role in aspects of mRNA polyadenylation that are specific
to higher vertebrates, perhaps being critical for important
features of neural functions such as myelination [53].
In surveying rodent and human neuronal and glial cell
lines (Figure 5), we obtained data suggesting that βCstF-
64 expression was restricted to neurons in the nervous sys-
tem. Even though we did not detect βCstF-64 in any of the
glial cell lines examined, we do not rule out the possibility
that it might be expressed in normal glial cells. Detailed
immunohistochemical analysis of brain slices will pro-
vide a better understanding of βCstF-64 expression in
neurons and glia.
We obtained data suggesting that βCstF-64 was expressed
in cell lines that represent neural progenitor cells and are
neuroendocrine in nature (Figure 5). For example, we
found evidence for βCstF-64 expression in neural-crest
derived cell lines such as CA-77 and thyroid carcinoma
cells. We also obtained data suggesting that while βCstF-
64 was expressed in undifferentiated and NGF-differenti-
ated PC-12 cell lines (Figure 5), it was not expressed in
adrenal gland (Figure 4). PC-12 cells, unlike adrenal chro-
maffin cells, are thought to possess the pluripotency of
primitive progenitor cells such as neural crest cells. These
data support the hypothesis that βCstF-64 is important for
neuronal gene expression.
What might be the function of βCstF-64 in the nervous
system? Our finding that βCstF-64 was expressed through-
out the nervous system and at different stages of develop-
ment suggests that it might be important for global neural
gene expression and brain function. Several studies have
indicated that many neural mRNAs have multiple polya-
denylation sites in their 3' UTRs or use sites that differ
from those in other tissues. Many of these mRNAs have
regulatory elements surrounding the alternative polyade-
nylation sites. Differential use of polyadenylation sites
within the 3' UTR has been shown to regulate translation
[17], stability [54], and rate of transcription [54] of these
neural mRNAs. It has been hypothesized that tissue-spe-
cific use of polyadenylation sites in these mRNAs might
be due to the expression of nervous system-specific poly-
adenylation factors [15]. Our discovery of the nervous sys-
tem-specific βCstF-64 splice variant supports the above
hypothesis, and leads us to propose that βCstF-64 might
recognize alternative polyadenylation signals in these
mRNAs contributing to their neural-specific expression. It
is possible that βCstF-64 might also contribute to the gen-
eration of protein isoforms specific to the nervous system
by use of internal poly(A) sites found in many neural
mRNAs [29-31].
How might βCstF-64 function in neural mRNA polyade-
nylation? In one model, βCstF-64 might recognize RNA
sequence elements that are specific to nervous system-
expressed polyadenylation sites. A similar model has been
proposed for the testis-expressed τCstF-64 variant [35,55].
A bioinformatic survey revealed that the downstream U/
GU-rich sequences in the pre-mRNA are enriched in nerv-
ous system-specific transcripts, lending plausibility to this
model [6]. How might βCstF-64 recognize these variant
RNA sequence elements if its RNA-binding domain is the
same as CstF-64? The insertion in βCstF-64 in the proline/
glycine-rich domain might alter the conformation of that
domain which might in turn affect the conformation of
the RNA-binding domain and alter the RNA binding spe-
cificities of βCstF-64 or otherwise affect the overall rate of
polyadenylation [56]. In another model, the insertion of
the βCstF-64 domain might alter the overall structure of
the CstF complex (for example, its dimerization, [57]),
affecting its interaction with CPSF or other components of
the polyadenylation machinery.BMC Molecular Biology 2009, 10:22 http://www.biomedcentral.com/1471-2199/10/22
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For a final model, we note that the 49 amino acid βCstF-
64 domain is not similar to any other known protein
domains (data not shown). Based on this, we speculate
that the βCstF-64 domain might be a previously unde-
scribed protein-protein interaction domain. It is possible
that βCstF-64 interacts with as-of-yet unknown nervous
system-specific polyadenylation factors or brings about
new interactions within the polyadenylation complex. It
might also interact with the splicing machinery since
splicing factors are known to modulate polyadenylation
efficiency [58-60]. Any of these proposed interactions
could help βCstF-64 in generating protein isoforms via
recognition of internal intronic and exonic poly(A) sites
thus increasing proteomic diversity in the nervous system.
Methods
Animals and RNA Samples
All animal studies were conducted in accordance with the
National Institutes of Health guidelines and all protocols
were approved by the TTUHSC Institutional Animal Care
and Use Committee. Tissues from adult male and female
CD-1 mice (Charles River Laboratories, Wilmington, DE)
were dissected post-euthanasia and stored in RNAlater
(Ambion, Austin, TX). Brains from mouse embryos at
days 15, 19, and 21 days post-coitus (dpc) were dissected
from the gravid females post-euthanasia. The first day on
which a vaginal plug was observed in the female, after
mating, was considered as 1 dpc. Human brain, liver and
testis RNA samples purchased from Ambion (Austin, TX)
were from single individuals. Slider turtle (Trachemys
scripta elegans) brain and liver RNA and 13-lined ground
squirrel (Spermophilus tridecemlineatus) brain RNA were
obtained from B. Dass (TTUHSC, Lubbock, TX) and Alli-
gator (Alligator mississippiensis) custom cDNA library was a
gift from Phil Hartig (US-EPA). Monodelphis tissues were
provided by Janice MacRossin and John L. VandeBerg
(Southwest Foundation for Biomedical Research).
RNA Analysis and RT-PCR
Different regions of the brain and indicated mouse tissues
were dissected, total RNA extracted by using TRIzol rea-
gent (Invitrogen, Carlsbad, CA), and treated with TurboD-
Nase (Ambion). Equal amounts of DNased RNA (4 μg)
from each tissue sample were used to synthesize cDNA
using SuperScriptII Reverse Transcriptase and oligo-dT
according to the manufacturer's protocol (Invitrogen).
Polymerase chain reaction (PCR, 30 cycles) was con-
ducted using the indicated primers (see Table 1) in an Air
Thermocycler (Idaho Technologies, Salt Lake City, UT).
Amplicons were resolved by electrophoresis on a 1% aga-
rose gel electrophoresis. Ethidium bromide stained RT-
PCR products were excised from the gel (Qiagen, Valencia,
CA), cloned using Topo II system (Invitrogen), and iden-
tified by DNA sequence analysis.
Cloning and Plasmids
The plasmid encoding full length βCstF-64 fused to the
FLAG epitope tag [61] (3XFLAG-βCstF-64) was created as
follows: mouse brain cDNA was subjected to RT-PCR
using primers X and Y containing HinDIII, KpnI restric-
tion sites (Table 1) and ligated into a 3X-HA vector encod-
ing full length CstF-64 (kind gift of K. W. McMahon)
digested by the same enzymes. Note that this vector also
contained the MS2 RNA binding domain though that did
not interfere with its expression or antigenicity. The
3XFLAG-βCstF-64 plasmid was created by amplifying full
length βCstF-64 using primers E and F containing XbaI,
BglII sites (Table 1) using 3X-HA-βCstF-64 as template.
This fragment was digested with Xba I and Bgl II, and
ligated into a similarly digested 3XFLAG-CstF-64 vector.
The cloning scheme of 3XFLAG-CstF-64 is described in
[61].
Cell Culture and Transfections
HeLa cells were grown at 37°C in 5% CO2 in Dulbecco's
Minimal Eagle Media (CellGro, Manassas, VA) containing
10% cosmic calf serum and 1% penicillin/streptomycin
(Gibco). HeLa cells were seeded in 6-well plates at a den-
sity of 300,000 cells/well and transfected the next day
with 800 ng of the indicated plasmids using Lipo-
fectamine (Invitrogen). Cells were harvested 48 hours
post-transfection by rinsing with ice-cold PBS, and lysed
in SDS loading buffer [62].
Antibodies
The following antibodies were used in this study: anti-α-
tubulin and anti-FLAG antibodies (Sigma, St. Louis, MO);
anti-CstF-64 antibody (3A7, [44]) and anti-βCstF-64 cus-
tom antibody generated in rabbits by Genscript Corpora-
tion (Piscataway, NJ) by injection of the peptide
GPAGPASIERVQGQRT representing part of the βCstF-64
insert.
Protein Analysis
For protein analysis, nuclear extract was prepared from
indicated mouse tissues [63], boiled and sonicated in SDS
loading buffer [62]. Protein concentration was measured
using the bicinchoninic acid (Pierce, Rockford, IL) assay.
Equal amounts of protein from the indicated tissues (20
μg) or HeLa cells were resolved by 10% SDS-PAGE, and
transferred to nitrocellulose membranes for immunoblot-
ting. For immunoblotting using anti-CstF-64 antibody,
membranes were blocked with Tris-buffered saline con-
taining 0.2% Tween-20 (TBST) with 2% nonfat dry milk
(TBST) for 2 hours and treated with anti-CstF-64 antibody
[44] at a dilution of 1:50. For immunoblotting using anti-
βCstF-64 antibody, the membrane was first treated with
0.2 mM glycine-HCl, pH 2.6 for 30 minutes at room tem-
perature, and rinsed extensively with TBST. Pre-treatment
with glycine at low pH was found to enhance the effective-
ness of this antibody while decreasing non-specific back-BMC Molecular Biology 2009, 10:22 http://www.biomedcentral.com/1471-2199/10/22
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ground. The membrane was then blocked with 2% nonfat
dry milk in TBST for 2 hours. The anti-βCstF-64 antibody
was used at a dilution of 1:5000 in 2% nonfat dry milk in
TBST, 0.05% Empigen (Calbiochem, La Jolla, CA). In the
peptide blocking experiment, the anti-βCstF-64 antibody
(1 μg/μL) was incubated with 10 fold excess peptide (10
μg) in 2% nonfat dry milk in TBST for 2 hours at room
temperature before addition to the membrane. Mem-
branes were subsequently treated with horseradish perox-
idase-conjugated goat anti-mouse and anti-rabbit IgG
(1:2500) and immunoreactive bands were visualized by
chemiluminescence using the Pierce SuperSignal kit
(Rockford, IL).
Two dimensional-PAGE Analysis
Nuclear extracts from mouse brain and liver were pre-
pared as described above. Protein concentration was esti-
mated by BCA assay. 392 μL of rehydration buffer (9 M
urea, 2% Triton X-100), 8 μL IPG buffer (pH 4–7) (Amer-
sham Biosciences, Piscataway, NJ) and 0.5 μL 1 M DTT
was added to 80 μg of nuclear protein. The mix was lay-
ered over a 7 cm pH 3–10 immobiline strip (Amersham
Biosciences) and allowed to rehydrate for 16 hours. The
strips were then subjected to isoelectric focusing at the fol-
lowing voltages: 200 V for 1 minute, 500 V for 20 minutes,
1000, 1500, 2000, 2500 V for 20 minutes and 3500 V for
60 minutes. The strip was equilibrated in equilibration
solution (20% SDS, 50 mM Tris, pH 8.8, 6 M urea, 30%
glycerol) containing 65 mM DTT but no iodoacetamide
for 15 minutes and then in equilibration solution con-
taining 135 mM iodoacetamide but no DTT for 15 min-
utes. The strip was then placed horizontally on a 10% SDS
gel, subjected to denaturing PAGE and immunoblot anal-
ysis.
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